However, in 59 consecutive patients with type 2 diabetes admitted for ADHF and randomized to empagliflozin vs. placebo seven days after randomization, the NT-proBNP level was significantly lower in the empagliflozin group than in the conventional glucose-lowering therapy group [118]. This evidence concerns the gene NPPB and type 2 diabetes mellitus.